Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

HDL and Reverse Cholesterol Transport.

Ouimet M, Barrett TJ, Fisher EA.

Circ Res. 2019 May 10;124(10):1505-1518. doi: 10.1161/CIRCRESAHA.119.312617.

PMID:
31071007
3.
4.

High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity.

Rohatgi A.

Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):32-40. doi: 10.1016/j.pcad.2015.05.004. Epub 2015 May 9. Review.

5.

Cholesterol efflux and reverse cholesterol transport.

Favari E, Chroni A, Tietge UJ, Zanotti I, Escolà-Gil JC, Bernini F.

Handb Exp Pharmacol. 2015;224:181-206. doi: 10.1007/978-3-319-09665-0_4. Review.

PMID:
25522988
6.

Reverse cholesterol transport and cholesterol efflux in atherosclerosis.

Ohashi R, Mu H, Wang X, Yao Q, Chen C.

QJM. 2005 Dec;98(12):845-56. Epub 2005 Oct 28. Review.

PMID:
16258026
7.

High-density lipoprotein heterogeneity and function in reverse cholesterol transport.

Rothblat GH, Phillips MC.

Curr Opin Lipidol. 2010 Jun;21(3):229-38. Review.

8.

HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target.

Bhatt A, Rohatgi A.

Curr Atheroscler Rep. 2016 Jan;18(1):2. doi: 10.1007/s11883-015-0554-1. Review.

PMID:
26710794
9.

microRNAs in lipoprotein metabolism and cardiometabolic disorders.

Rotllan N, Price N, Pati P, Goedeke L, Fernández-Hernando C.

Atherosclerosis. 2016 Mar;246:352-60. doi: 10.1016/j.atherosclerosis.2016.01.025. Epub 2016 Jan 18. Review.

10.

High-density lipoprotein-based drug discovery for treatment of atherosclerosis.

Du Y, Wang L, Hong B.

Expert Opin Drug Discov. 2015;10(8):841-55. doi: 10.1517/17460441.2015.1051963. Epub 2015 May 28. Review.

PMID:
26022101
11.

Therapeutic interventions targeted at the augmentation of reverse cholesterol transport.

Toth PP, Davidson MH.

Curr Opin Cardiol. 2004 Jul;19(4):374-9. Review.

PMID:
15218399
12.

[Role of HDL in Cholesterol Efflux and Reverse Cholesterol Transport].

Ayaori M.

Rinsho Byori. 2016 Jan;64(1):57-65. Review. Japanese.

PMID:
27192798
13.

Reverse cholesterol transport in familial hypercholesterolemia.

Guerin M.

Curr Opin Lipidol. 2012 Aug;23(4):377-85. doi: 10.1097/MOL.0b013e328353ef07. Review.

PMID:
22510809
14.

Reverse cholesterol transport in type 2 diabetes mellitus.

Tan KC.

Diabetes Obes Metab. 2009 Jun;11(6):534-43. doi: 10.1111/j.1463-1326.2008.01012.x. Epub 2009 Jan 19. Review.

PMID:
19175378
15.

High density lipoprotein (HDL) particles from end-stage renal disease patients are defective in promoting reverse cholesterol transport.

Anderson JL, Gautier T, Nijstad N, Tölle M, Schuchardt M, van der Giet M, Tietge UJ.

Sci Rep. 2017 Feb 2;7:41481. doi: 10.1038/srep41481.

16.

High-Density Lipoprotein Proteomic Composition, and not Efflux Capacity, Reflects Differential Modulation of Reverse Cholesterol Transport by Saturated and Monounsaturated Fat Diets.

O'Reilly M, Dillon E, Guo W, Finucane O, McMorrow A, Murphy A, Lyons C, Jones D, Ryan M, Gibney M, Gibney E, Brennan L, de la Llera Moya M, Reilly MP, Roche HM, McGillicuddy FC.

Circulation. 2016 May 10;133(19):1838-50. doi: 10.1161/CIRCULATIONAHA.115.020278. Epub 2016 Apr 14.

17.

Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.

Breevoort SR, Angdisen J, Schulman IG.

Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1650-60. doi: 10.1161/ATVBAHA.114.303383. Epub 2014 Jun 19.

18.

The macrophage and its related cholesterol efflux as a HDL function index in atherosclerosis.

Yamamoto S, Narita I, Kotani K.

Clin Chim Acta. 2016 Jun 1;457:117-22. doi: 10.1016/j.cca.2016.04.012. Epub 2016 Apr 15. Review.

PMID:
27087419
19.
20.

Enhanced atheroprotection and lesion remodelling by targeting the foam cell and increasing plasma cholesterol acceptors.

Son SH, Goo YH, Choi M, Saha PK, Oka K, Chan LC, Paul A.

Cardiovasc Res. 2016 Feb 1;109(2):294-304. doi: 10.1093/cvr/cvv241. Epub 2015 Oct 20.

Supplemental Content

Support Center